Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multicomponent meningococcal b vaccine (Sanofi)
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The multicomponent meningococcal B vaccine (SP MenB) is an investigational recombinant vaccine being developed by Sanofi Pasteur for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroup B. The vaccine is designed to elicit a broad bactericidal antibody response by targeting multiple surface-exposed protein antigens, specifically factor H-binding protein (fHbp), Neisserial heparin-binding antigen (NHBA), Neisseria adhesin A (NadA), and outer membrane vesicle (OMV) components. It is currently in Phase 1 clinical development (NCT04825223), where its safety and immunogenicity are being evaluated across various age groups, including infants, toddlers, adolescents, and adults. The vaccine is being studied as a standalone product and in co-administration with other vaccines, such as MenQuadfi (a MenACYW conjugate vaccine), and is being compared to licensed MenB vaccines like Bexsero and Trumenba.
- Other names
- meningococcal group b vaccineinvestigational multicomponent meningococcal group B vaccine
02
Targets
fHbp (Factor H-binding protein)NadA (Neisserial adhesin A)Neisserial heparin-binding antigen (NHBA) and outer membrane vesicle (OMV) antigensNHBA (Neisserial heparin-binding antigen)MenB OMV (Neisseria meningitidis serogroup B outer membrane vesicle)
Beyond the preview
Go deeper on multicomponent meningococcal b vaccine (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multicomponent meningococcal b vaccine (Sanofi).